Skip to main content

Genomic Alterations in Hodgkin’s Lymphoma

International Journal of Hematology volume 83, pages 379–384 (2006)Cite this article

Abstract

Cytogenetic analysis of Hodgkin’s lymphoma (HL) is hampered by the scarcity of neoplastic cells within a sea of reactive cells. There is accumulating evidence that HL represents 2 disease entities, classic HL (cHL) with its morphologic variants and nodular lymphocyte predominant HL (NLPHL). This subdivision, initially worked out in morphologic and immunohisto-chemical studies, has been further substantiated by molecular cytogenetic investigations. Two recurrent chromosomal aberrations, namely gains of 2p13–p16 and 9p24, have been found by comparative genomic hybridization analysis in microdissected cells from cHL patients as well as in cHL cell lines, but not in NLPHL cells. The available cHL cell lines are remarkably heterogeneous in their karyotypes, suggesting profound genomic instability leading to numeric chromosomal aberration and multiple chromosomal breaks and translocations. In this article, we review genomic aberrations that may contribute to the development and maintenance of the morphologic and clinical presentation of these B-cell lymphoma entities. Furthermore, we delineate current data on the genomic changes observed in the neoplastic cells of HL that are created by epigenetic mechanisms, which are alternative mechanisms that regulate the expression of relevant genes.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

    Google Scholar 

  2. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Brauninger A. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood. 2005;105:4051–4059.

    Article  CAS  Google Scholar 

  3. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–550.

    Article  CAS  Google Scholar 

  4. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283–4297.

    Article  CAS  Google Scholar 

  5. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin’s disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001;38:368–375.

    Article  CAS  Google Scholar 

  6. Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin’s disease. Leuk Lymphoma. 2000;38:363–371.

    Article  CAS  Google Scholar 

  7. Oshima Y, Puri RK. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist. Cell Immunol. 2001;211:37–42.

    Article  CAS  Google Scholar 

  8. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol. 2002;13(suppl 1):52–56.

    Article  Google Scholar 

  9. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol. 2002;55:162–176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin’s lymphoma. J Clin Oncol. 2005;23:6379–6386.

    Article  CAS  Google Scholar 

  11. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 2005;105:4553–4560.

    Article  CAS  Google Scholar 

  12. Kuppers R. Molecular biology of Hodgkin’s lymphoma. Adv Cancer Res. 2002;84:277–312.

    Article  Google Scholar 

  13. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251–262.

    Article  CAS  Google Scholar 

  14. Yonetani N, Kurata M, Nishikori M, et al. Primary mediastinal large B-cell lymphoma: a comparative study with nodular sclerosis-type Hodgkin’s disease. Int J Hematol. 2001;74:178–185.

    Article  CAS  Google Scholar 

  15. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lym-phoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411–1421.

    Article  Google Scholar 

  16. Poppema S, Kluiver JL, Atayar C, et al. Report: workshop on medi-astinal grey zone lymphoma. Eur J Haematol Suppl. 2005:45–52.

    Article  Google Scholar 

  17. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101:1220–1235.

    Article  CAS  Google Scholar 

  18. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–627.

    Article  CAS  Google Scholar 

  19. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649.

    Article  CAS  Google Scholar 

  20. Gollin SM. Chromosomal instability. Curr Opin Oncol. 2004;16:25–31.

    Article  Google Scholar 

  21. Gollin SM. Mechanisms leading to chromosomal instability. Semin Cancer Biol. 2005;15:33–42.

    Article  CAS  Google Scholar 

  22. Re D, Zander T, Diehl V, Wolf J. Genetic instability in Hodgkin’s lymphoma. Ann Oncol. 2002;13(suppl 1):19–22.

    Article  Google Scholar 

  23. Saunders W. Centrosomal amplification and spindle multipolarity in cancer cells. Semin Cancer Biol. 2005;15:25–32.

    Article  CAS  Google Scholar 

  24. Kramer A, Neben K, Ho AD. Centrosome aberrations in hemato-logical malignancies. Cell Biol Int. 2005;29:375–383.

    Article  CAS  Google Scholar 

  25. Kramer A, Schweizer S, Neben K, et al. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin’s lymphoma. Leukemia. 2003;17:2207–2213.

    Article  CAS  Google Scholar 

  26. Falzetti D, Crescenzi B, Matteuci C, et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin’s disease. Haematologica. 1999;84:298–305.

    PubMed  CAS  Google Scholar 

  27. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60:549–552.

    PubMed  CAS  Google Scholar 

  28. Martin-Subero JI, Knippschild U, Harder L, et al. Segmental chromosomal aberrations and centrosome amplifications: pathogenetic mechanisms in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma? Leukemia. 2003;17:2214–2219.

    Article  CAS  Google Scholar 

  29. Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998;58:3974–3985.

    PubMed  CAS  Google Scholar 

  30. Joos S, Granzow M, Holtgreve-Grez H, et al. Hodgkin’s lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer. 2003;103: 489–495.

    Article  CAS  Google Scholar 

  31. Duval A, Raphael M, Brennetot C, et al. The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A. 2004;101:5002–5007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Re D, Benenson L, Wickenhauser C, et al. Proficient mismatch repair protein expression in Hodgkin and Reed Sternberg cells. Int J Cancer. 2002;97:205–210.

    Article  CAS  Google Scholar 

  33. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96:808–822.

    PubMed  CAS  Google Scholar 

  34. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translo-cations in B cell lymphomas. Oncogene. 2001;20:5580–5594.

    Article  CAS  Google Scholar 

  35. Vanasse GJ, Concannon P, Willerford DM. Regulated genomic instability and neoplasia in the lymphoid lineage. Blood. 1999;94:3997–4010.

    PubMed  CAS  Google Scholar 

  36. Gravel S, Delsol G, Al Saati T. Single-cell analysis of the t(14;18) (q32;q21) chromosomal translocation in Hodgkin’s disease demonstrates the absence of this translocation in neoplastic Hodgkin and Reed-Sternberg cells. Blood. 1998;91:2866–2874.

    PubMed  CAS  Google Scholar 

  37. Sarris AH, Luthra R, Papadimitracopoulou V, et al. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin’s lymphomas, Hodgkin’s disease, or lymphomatoid papulosis. Blood. 1996;88:1771–1779.

    PubMed  CAS  Google Scholar 

  38. Chaganti SR, Chen W, Parsa N, et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer. 1998;23:323–327.

    Article  CAS  Google Scholar 

  39. Ohno H. Pathogenetic role of BCL6 translocation in B-cell non- Hodgkin’s lymphoma. Histol Histopathol. 2004;19:637–650.

    PubMed  CAS  Google Scholar 

  40. Jardin F, Ruminy P, Parmentier F, et al. Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma. Leukemia. 2005;19:1824–1830.

    Article  CAS  Google Scholar 

  41. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6:1054–1060.

    Article  CAS  Google Scholar 

  42. Jardin F, Sahota SS. Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis. Hematology. 2005;10:115–129.

    Article  CAS  Google Scholar 

  43. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood. 2003;101:706–710.

    Article  CAS  Google Scholar 

  44. Renne C, Martin-Subero JI, Hansmann ML, Siebert R. Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin’s lymphoma reveal a recurrent IGH- BCL6 juxtaposition. J Mol Diagn. 2005;7:352–356.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Chui DT, Hammond D, Baird M, Shield L, Jackson R, Jarrett RF. Classical Hodgkin lymphoma is associated with frequent gains of 17q. Genes Chromosomes Cancer. 2003;38:126–136.

    Article  CAS  Google Scholar 

  46. Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99:1381–1387.

    Article  CAS  Google Scholar 

  47. Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101:3681–3686.

    Article  CAS  Google Scholar 

  48. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005;24:8259–8267.

    Article  CAS  Google Scholar 

  49. Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res. 2005;65:439–447.

    PubMed  CAS  Google Scholar 

  50. Barth TF, Bentz M, Leithauser F, et al. Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer. 2001;31:316–325.

    Article  CAS  Google Scholar 

  51. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 2001;30:393–401.

    Article  CAS  Google Scholar 

  52. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 1996;87:1571–1578.

    PubMed  CAS  Google Scholar 

  53. Goldin LR, McMaster ML, Ter-Minassian M, et al. A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. J Med Genet. 2005;42: 595–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gebhart E. Genomic imbalances in human leukemia and lym-phoma detected by comparative genomic hybridization (review). Int J Oncol. 2005;27:593–606.

    PubMed  CAS  Google Scholar 

  55. Ohshima K, Haraoka S, Yoshioka S, et al. Chromosome 16q deletion and loss of E-cadherin expression in Hodgkin and Reed-Sternberg cells. Int J Cancer. 2001;92:678–682.

    Article  CAS  Google Scholar 

  56. Re D, Starostik P, Massoudi N, et al. Allelic losses on chromosome 6q25 in Hodgkin and Reed Sternberg cells. Cancer Res. 2003;63:2606–2609.

    PubMed  CAS  Google Scholar 

  57. Lespinet V, Terraz F, Recher C, et al. Single-cell analysis of loss of heterozygosity at the ATM gene locus in Hodgkin and Reed-Stern- berg cells of Hodgkin’s lymphoma: ATM loss of heterozygosity is a rare event. Int J Cancer. 2005;114:909–916.

    Article  CAS  Google Scholar 

  58. Maggio EM, van den Berg A, de Jong D, Diepstra A, Poppema S. Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin’s lymphoma. Am J Pathol. 2003;162:29–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Franke S, Wlodarska I, Maes B, et al. Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. Blood. 2001;97:1845–1853.

    Article  CAS  Google Scholar 

  60. Rodig SJ, Savage KJ, Nguyen V, et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol. 2005;29:196–203.

    Article  Google Scholar 

  61. Xiao Q, Shen N, Hedvat CV, et al. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2004;12:211–215.

    Article  CAS  Google Scholar 

  62. Staudt LM. The molecular and cellular origins of Hodgkin’s disease. J Exp Med. 2000;191:207–212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99:1474–1477.

    Article  CAS  Google Scholar 

  64. Liu P, Keller JR, Ortiz M, et al. Bcl11a is essential for normal lym-phoid development. Nat Immunol. 2003;4:525–532.

    Article  CAS  Google Scholar 

  65. Kuppers R, Sonoki T, Satterwhite E, et al. Lack of somatic hyper-mutation of IG V(H) genes in lymphoid malignancies with t(2;14) (p13;q32) translocation involving the BCL11A gene. Leukemia. 2002;16:937–939.

    Article  CAS  Google Scholar 

  66. Satterwhite E, Sonoki T, Willis TG, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 2001;98:3413–3420.

    Article  CAS  Google Scholar 

  67. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3:900–911.

    Article  CAS  Google Scholar 

  68. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma- derived cell lines supports cell survival. Cell Signal. 2006;18:449–455.

    Article  CAS  Google Scholar 

  69. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618–626.

    Article  CAS  Google Scholar 

  70. O’Shea JJ, Watford W. A peek at PIAS. Nat Immunol. 2004;5:875–876.

    Article  CAS  Google Scholar 

  71. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004;103:4630–4635.

    Article  CAS  Google Scholar 

  72. Chim CS, Wong KY, Loong F, Srivastava G. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lym-phoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia. 2004;18:356–358.

    Article  CAS  Google Scholar 

  73. Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105:2535–2542.

    Article  CAS  Google Scholar 

  74. Melzner I, Weniger MA, Bucur AJ, et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer. 2006;118:1941–1944.

    Article  CAS  Google Scholar 

  75. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679–2684.

    Article  CAS  Google Scholar 

  76. Baus D, Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer. 2006;118:1404–1413.

    Article  CAS  Google Scholar 

  77. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell. 2002;2:9–15.

    Article  CAS  Google Scholar 

  78. Kupper M, Joos S, von Bonin F, et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol. 2001;112:768–775.

    Article  CAS  Google Scholar 

  79. Sanchez-Aguilera A, Garcia JF, Sanchez-Beato M, Piris MA. Hodgkin’s lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene. 2006;25:2565–2574.

    Article  CAS  Google Scholar 

  80. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;20:1–13.

    Article  CAS  Google Scholar 

  81. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2(suppl 1):S4-S11.

    Article  CAS  Google Scholar 

  82. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J, Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin’s and CD30-positive non-Hodgkin’s lymphomas. Am J Pathol. 2002;161:1007–1013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Murray PG, Qiu GH, Fu L, et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin’s lymphoma. Oncogene. 2004;23:1326–1331.

    Article  CAS  Google Scholar 

  84. Sanchez-Aguilera A, Delgado J, Camacho FI, et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood. 2004;103:2351–2357.

    Article  CAS  Google Scholar 

  85. Ushmorov A, Ritz O, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood. 2004;104:3326–3334.

    Article  CAS  Google Scholar 

  86. Ushmorov A, Leithauser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107:2493–2500.

    Article  CAS  Google Scholar 

  87. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496–501.

    Article  CAS  Google Scholar 

  88. Raaphorst FM. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet. 2005;14(spec no 1):R93-R100.

    Article  CAS  Google Scholar 

  89. Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439:871–874.

    Article  CAS  Google Scholar 

  90. Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am J Pathol. 2004;164:873–881.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005;65:3509–3512.

    Article  CAS  Google Scholar 

  92. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6:376–385.

    Article  CAS  Google Scholar 

  93. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243–249.

    Article  CAS  Google Scholar 

  94. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102:3627–3632.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Pathology, University of Ulm, Albert-Einstein-Allee 11, 89081, Ulm, Germany

    Marc A. Weniger, Thomas F. E. Barth & Peter Möller

Authors
  1. Marc A. Weniger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas F. E. Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Möller.

About this article

Cite this article

Weniger, M.A., Barth, T.F.E. & Möller, P. Genomic Alterations in Hodgkin’s Lymphoma. Int J Hematol 83, 379–384 (2006). https://doi.org/10.1532/IJH97.06048

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.06048

Key words

  • Hodgkin’s lymphoma
  • Genomic instability
  • Cytogenetics
  • Chromosomal aberration
  • Translocation
  • Epigenetics